Your AI-Trained Oncology Knowledge Connection!
Vamsidhar Velcheti, MD, highlights the advancement of CTLA-4–based combinations in non–small cell lung cancer treatment, the emergence of antibody-drug conjugates in non–small cell lung cancer, and the impact of the POSEIDON trial on the treatment landscape.
Vamsidhar Velcheti, MD, discusses the evaluation of immunotherapy combination regimens for patients with metastatic non–small cell lung cancer.
Jorge M. Mercado, MD, discusses the effect of the COVID-19 pandemic on lung cancer screening.
OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.
Dr Velcheti discusses planned research into whether mobile technology services can improve patient outcomes for underserved and underrepresented patient populations.
NYU Langone Health has been recognized as No. 1 in quality and safety for inpatient and ambulatory care by Vizient, Inc.
To really advance equity in cancer care, we must think long and hard about where we apply innovation and how we measure success.
During the past 15 years, breakthrough discoveries have revolutionized the treatment landscape for most patients with lung cancer, progress that has helped fuel an overall drop in cancer mortality.
Aasma Shaukat, MD, MPH, discusses the benefit of diverse enrollment in clinical trials in colorectal cancer.
David R. Wise, MD, PhD, discusses unmet needs in the standard of care in prostate cancer.
Vamsidhar Velcheti, MD, discusses the safety of nemvaleukin alfa in patients with advanced solid tumors in the phase 1/2 ARTISTRY-1 trial.
Adagrasib led to an intracranial objective response rate of 32% and a median intracranial duration of response that was not reached in patients with KRAS G12C–mutant non–small cell lung cancer and active, untreated CNS metastases, according to findings from the KRYSTAL-1 trial.
Paul E. Oberstein, MD, discusses remaining challenges in metastatic colorectal cancer.
Paul E. Oberstein, MD, discusses the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.
Paul E. Oberstein, MD, discusses the utilization of ctDNA in metastatic colorectal cancer.
Dr D’Abreo discusses adverse effects that are common in metastatic breast cancer, shares advice on establishing an open channel of communication with patients, and highlights preventive and proactive management strategies for treatment-related adverse effects.
Paul E. Oberstein, MD, discusses the current treatment landscape of colorectal cancer.
Oliva Lara, MD, discusses the connection between molecular differences and disparities in cancer care in uterine serous carcinomas, as examined in a retrospective cohort study.
Faith E. Davies, MD, a nationally renowned hematology expert, has been appointed the inaugural director of the Center for Blood Cancers at NYU Langone Health’s Perlmutter Cancer Center.
Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the qualities that make someone a great mentor for an oncology fellow.
Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the process of selecting applicants to be accepted into an oncology fellowship.
Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss whether it's still a possibility to be a general oncologist following an oncology fellowship.
Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the compact style that comprises oncology fellowship training.
Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, share advice in selecting a mentor during an oncology fellowship.
Sarah Lee, MD, MBA, discusses the association of microsatellite instability–high, mismatch repair deficiency, and tumor mutational burden–high features in endometrial cancer.
Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, share their experiences as a fellowship director and an oncology fellow, respectively.
Jeffrey S. Weber, MD, PhD, overviews the successes made in the melanoma setting in the past decade and the challenges to overcome in the future.
Jeffrey S. Weber, MD, PhD, discusses unmet needs in ocular and mucosal melanoma.
Bhavana Pothuri, MD, discusses the challenges of DNA polymerase epsilon mutation testing in endometrial cancer.
Joshua K. Sabari, MD, discusses selecting between available ALK inhibitors in ALK-positive non–small cell lung cancer.
